IBDEI171 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19178,2)
 ;;=^5007486
 ;;^UTILITY(U,$J,358.3,19179,0)
 ;;=I69.092^^93^989^30
 ;;^UTILITY(U,$J,358.3,19179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19179,1,3,0)
 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,19179,1,4,0)
 ;;=4^I69.092
 ;;^UTILITY(U,$J,358.3,19179,2)
 ;;=^5007422
 ;;^UTILITY(U,$J,358.3,19180,0)
 ;;=I69.892^^93^989^32
 ;;^UTILITY(U,$J,358.3,19180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19180,1,3,0)
 ;;=3^Facial weakness following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,19180,1,4,0)
 ;;=4^I69.892
 ;;^UTILITY(U,$J,358.3,19180,2)
 ;;=^5007548
 ;;^UTILITY(U,$J,358.3,19181,0)
 ;;=I69.351^^93^989^34
 ;;^UTILITY(U,$J,358.3,19181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19181,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right dominant side
 ;;^UTILITY(U,$J,358.3,19181,1,4,0)
 ;;=4^I69.351
 ;;^UTILITY(U,$J,358.3,19181,2)
 ;;=^5007504
 ;;^UTILITY(U,$J,358.3,19182,0)
 ;;=I69.352^^93^989^33
 ;;^UTILITY(U,$J,358.3,19182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19182,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff left dominant side
 ;;^UTILITY(U,$J,358.3,19182,1,4,0)
 ;;=4^I69.352
 ;;^UTILITY(U,$J,358.3,19182,2)
 ;;=^5007505
 ;;^UTILITY(U,$J,358.3,19183,0)
 ;;=I69.353^^93^989^35
 ;;^UTILITY(U,$J,358.3,19183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19183,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right nondom side
 ;;^UTILITY(U,$J,358.3,19183,1,4,0)
 ;;=4^I69.353
 ;;^UTILITY(U,$J,358.3,19183,2)
 ;;=^5007506
 ;;^UTILITY(U,$J,358.3,19184,0)
 ;;=I69.354^^93^989^36
 ;;^UTILITY(U,$J,358.3,19184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19184,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc affecting left nondom side
 ;;^UTILITY(U,$J,358.3,19184,1,4,0)
 ;;=4^I69.354
 ;;^UTILITY(U,$J,358.3,19184,2)
 ;;=^5007507
 ;;^UTILITY(U,$J,358.3,19185,0)
 ;;=I69.151^^93^989^39
 ;;^UTILITY(U,$J,358.3,19185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19185,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff right dominant side
 ;;^UTILITY(U,$J,358.3,19185,1,4,0)
 ;;=4^I69.151
 ;;^UTILITY(U,$J,358.3,19185,2)
 ;;=^5007441
 ;;^UTILITY(U,$J,358.3,19186,0)
 ;;=I69.152^^93^989^37
 ;;^UTILITY(U,$J,358.3,19186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19186,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff left dominant side
 ;;^UTILITY(U,$J,358.3,19186,1,4,0)
 ;;=4^I69.152
 ;;^UTILITY(U,$J,358.3,19186,2)
 ;;=^5007442
 ;;^UTILITY(U,$J,358.3,19187,0)
 ;;=I69.153^^93^989^40
 ;;^UTILITY(U,$J,358.3,19187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19187,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff right nondom side
 ;;^UTILITY(U,$J,358.3,19187,1,4,0)
 ;;=4^I69.153
 ;;^UTILITY(U,$J,358.3,19187,2)
 ;;=^5007443
 ;;^UTILITY(U,$J,358.3,19188,0)
 ;;=I69.154^^93^989^38
 ;;^UTILITY(U,$J,358.3,19188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19188,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff left nondom side
 ;;^UTILITY(U,$J,358.3,19188,1,4,0)
 ;;=4^I69.154
 ;;^UTILITY(U,$J,358.3,19188,2)
 ;;=^5007444
 ;;^UTILITY(U,$J,358.3,19189,0)
 ;;=I69.851^^93^989^45
 ;;^UTILITY(U,$J,358.3,19189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19189,1,3,0)
 ;;=3^Hemiplga fol oth cerebvasc disease aff right dominant side
 ;;^UTILITY(U,$J,358.3,19189,1,4,0)
 ;;=4^I69.851
 ;;^UTILITY(U,$J,358.3,19189,2)
 ;;=^5007535
 ;;^UTILITY(U,$J,358.3,19190,0)
 ;;=I69.852^^93^989^46
